Filed by the Registrant | x | Filed by a party other than the Registrant | o |
o | Preliminary Proxy Statement | ||||
o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||
x | Definitive Proxy Statement | ||||
o | Definitive Additional Materials | ||||
o | Soliciting Material Pursuant to §240.14a-12 |
Immuneering Corporation | ||
(Name of Registrant as Specified in its Charter) |
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) |
x | No fee required | ||||
o | Fee paid previously with preliminary materials | ||||
o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
By Order of the Board of Directors, | ||||||||
Cambridge, Massachusetts May | /s/ Michael D. Bookman | |||||||
Michael D. Bookman Chief Legal Officer & Secretary |
Page | |||||||||||
Proposal | Votes Required | Voting Options | Impact of “Withhold” or “Abstain” Votes | Broker Discretionary Voting Allowed | |||||||||||||||||||||||||||
Proposal No. 1: Election of Directors | The plurality of the votes cast. This means that the two nominees receiving the highest number of affirmative “FOR” votes will be elected as Class | “FOR ALL” “WITHHOLD ALL” “FOR ALL EXCEPT” | None(1) | No(3) | |||||||||||||||||||||||||||
Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm | The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at the Annual Meeting by the holders entitled to vote thereon. | “FOR” “AGAINST” “ABSTAIN” | None(2) | Yes(4) |
Class I Director - Current Term Ending at 2025 Annual Meeting | Class II Director - Current Term Ending at 2023 Annual Meeting | Class III Director - Current Term Ending at 2024 Annual Meeting | ||||||||||||||||
Ann E. Berman | Peter Feinberg | Robert J. Carpenter | ||||||||||||||||
Diana F. Hausman, M.D. | Laurie B. Keating | Benjamin J. Zeskind, Ph.D. |
Class II Director Nominees | Age | Director Since | Current Position at Immuneering | |||||||||||||||||
Peter Feinberg | 62 | January 2021 | Director | |||||||||||||||||
Laurie B. Keating | 69 | March 2021 | Director |
Class I Directors | Age | Director Since | Current Position at Immuneering | |||||||||||||||||||||
Ann E. Berman | July 2021 | Director | ||||||||||||||||||||||
Diana F. Hausman, M.D. | January 2022 | Director |
Class III Directors | Age | Director Since | Current Position at Immuneering | |||||||||||||||||||||
Robert J. Carpenter | May 2009 | Chairman and Director | ||||||||||||||||||||||
Benjamin J. Zeskind, Ph.D. | February 2008 | Co-Founder, President, Chief Executive Officer, Director |
| | Fiscal Year 2021 | | Fiscal Year 2020 | | |||||||||||||||||||
Audit fees(1) | | | $ | 315,000 | | | | $ | 126,125 | | | |||||||||||||
Audit-related fees(2) | | | $ | 160,125 | | | | $ | — | | | |||||||||||||
Fiscal Year 2022 | Fiscal Year 2021 | |||||||||||||||||||||||
Audit fees(1)(2) | Audit fees(1)(2) | $ | 285,600 | $ | 315,255 | |||||||||||||||||||
Audit-related fees(3) | Audit-related fees(3) | $ | — | $ | 160,125 | |||||||||||||||||||
Tax fees | | | $ | — | | | | $ | — | | | Tax fees | $ | — | $ | — | ||||||||
All other fees | | | $ | — | | | | $ | — | | | All other fees | $ | — | $ | — | ||||||||
Total Fees | | | $ | 475,125 | | | | $ | 126,125 | | | Total Fees | $ | 285,600 | $ | 475,380 |
Name | | | Age | | | Position(s) | | | In Current Position Since | |
Benjamin J. Zeskind, Ph.D. | | | 40 | | | Co-Founder, President, Chief Executive Officer, Director | | | 2008 | |
Biren Amin | | | 49 | | | Chief Financial Officer, Treasurer | | | 2021 | |
Scott Barrett, M.D. | | | 59 | | | Chief Medical Officer | | | 2019 | |
Brett Hall, Ph.D. | | | 53 | | | Chief Scientific Officer | | | 2019 | |
Michael D. Bookman | | | 35 | | | General Counsel, Secretary | | | 2021 | |
Name | Age | Position(s) | In Current Position Since | |||||||||||||||||
Benjamin J. Zeskind, Ph.D. | 41 | Co-Founder, President, Chief Executive Officer, Director | 2008 | |||||||||||||||||
Harold E. Brakewood | 58 | Chief Business Officer | 2023 | |||||||||||||||||
Scott Barrett, M.D. | 60 | Chief Medical Officer | 2019 | |||||||||||||||||
Brett Hall, Ph.D. | 54 | Chief Scientific Officer | 2019 | |||||||||||||||||
Michael D. Bookman | 36 | Chief Legal Officer, Secretary | 2021 | |||||||||||||||||
Mallory Morales | 39 | Vice President, Finance and Treasurer | 2022 | |||||||||||||||||
Leah R. Neufeld | 51 | Chief People Officer | 2022 |
— Board size, independence and qualifications | — Stock ownership | ||||||||
— Executive sessions of independent directors | — Board access to senior management | ||||||||
— Board leadership structure | — Board access to independent advisors | ||||||||
— Selection of new directors | — Board self-evaluations | ||||||||
— Director orientation and continuing education | — Board meetings | ||||||||
— Limits on board service | — Meeting attendance by directors and non-directors | ||||||||
— Change of principal occupation | — Meeting materials | ||||||||
— Term limits | — Board committees, responsibilities and independence | ||||||||
— Director responsibilities | — Succession planning | ||||||||
— Director compensation | — Risk management |
Name | Audit Committee | Nominating and Corporate Governance Committee | Compensation Committee | |||||||||||||||||||||
Ann E. Berman | Chair | X | ||||||||||||||||||||||
Robert J. Carpenter | X | X | ||||||||||||||||||||||
Peter Feinberg | ||||||||||||||||||||||||
Diana F. Hausman, M.D. | ||||||||||||||||||||||||
Laurie B. Keating | X | Chair | ||||||||||||||||||||||
Benjamin J. Zeskind, Ph.D. |
Total Number of Directors (6 total) | | | | | | | | | | Total Number of Directors (6 total) | |||||||||||||||||||||||||||||||||||
| | Female | | Male | | Non- Binary | | Did Not Disclose Gender | | ||||||||||||||||||||||||||||||||||||
Female | Male | Non- Binary | Did Not Disclose Gender | ||||||||||||||||||||||||||||||||||||||||||
Part I: Gender Identity | | | | | | | | | | Part I: Gender Identity | |||||||||||||||||||||||||||||||||||
Directors | | 3 | | 3 | | — | | — | | Directors | 3 | 3 | — | — | |||||||||||||||||||||||||||||||
Part II: Demographic Background | | | | | | | | | | Part II: Demographic Background | |||||||||||||||||||||||||||||||||||
African American or Black | | — | | — | | — | | — | | African American or Black | — | — | — | — | |||||||||||||||||||||||||||||||
Alaskan Native or Native American | | — | | — | | — | | — | | Alaskan Native or Native American | — | — | — | — | |||||||||||||||||||||||||||||||
Asian | | — | | — | | — | | — | | Asian | — | — | — | — | |||||||||||||||||||||||||||||||
Hispanic or Latinx | | — | | — | | — | | — | | Hispanic or Latinx | — | — | — | — | |||||||||||||||||||||||||||||||
Native Hawaiian or Pacific Islander | | — | | — | | — | | — | | Native Hawaiian or Pacific Islander | — | — | — | — | |||||||||||||||||||||||||||||||
White | | 3 | | 3 | | — | | — | | White | 3 | 3 | — | — | |||||||||||||||||||||||||||||||
Two or More Races or Ethnicities | | — | | — | | — | | — | | Two or More Races or Ethnicities | — | — | — | — | |||||||||||||||||||||||||||||||
LGBTQ+ | | — | | LGBTQ+ | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Did Not Disclose Demographic Background | | — | | Did Not Disclose Demographic Background | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Directors who identify as Military Veterans | | — | | 1 | | — | | — | | Directors who identify as Military Veterans | — | 1 | — | — |
Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($)(1) | | | Option Awards ($)(2) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||||||||
Benjamin J. Zeskind, Ph.D. | | | | | 2021 | | | | | | 400,238(3) | | | | | | 421,041 | | | | | | 1,704,500 | | | | | | 18,492(4) | | | | | | 2,544,271 | | |
President and Chief Executive Officer | | | | | 2020 | | | | | | 292,550 | | | | | | 500,000 | | | | | | — | | | | | | 13,495 | | | | | | 806,045 | | |
Brett Hall, Ph. D | | | | | 2021 | | | | | | 630,000 | | | | | | 189,000 | | | | | | 1,704,500 | | | | | | 690(5) | | | | | | 2,524,190 | | |
Chief Scientific Officer | | | | | 2020 | | | | | | 615,000 | | | | | | 160,000 | | | | | | — | | | | | | 200 | | | | | | 775,200 | | |
Biren Amin | | | | | 2021 | | | | | | 312,500(6) | | | | | | 180,000 | | | | | | 2,769,472 | | | | | | 11,558(7) | | | | | | 3,273,530 | | |
Chief Financial Officer | | | | | 2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name and Principal Position | Year | Salary ($) | Bonus ($)(1) | Option Awards ($)(2) | All Other Compensation ($) | Total ($) | ||||||||||||||||||||||||||||||||||||||
Benjamin J. Zeskind, Ph.D. | 2022 | 570,285 | 313,657 | 1,156,550 | 14,474 | (3) | 2,054,966 | |||||||||||||||||||||||||||||||||||||
President and Chief Executive Officer | 2021 | 400,238 | 421,041 | 1,052,035 | 18,492 | (3) | 1,891,806 | |||||||||||||||||||||||||||||||||||||
Brett Hall, Ph.D. | 2022 | 652,050 | 215,177 | 487,199 | 690 | (4) | 1,355,116 | |||||||||||||||||||||||||||||||||||||
Chief Scientific Officer | 2021 | 630,000 | 189,000 | 1,052,035 | 690 | (4) | 1,871,725 | |||||||||||||||||||||||||||||||||||||
Scott Barrett, M.D. | 2022 | 504,000 | 138,600 | 421,242 | 14,180 | (5) | 1,078,022 | |||||||||||||||||||||||||||||||||||||
Chief Medical Officer |
Name | Vesting Start Date | Number of securities underlying unexercised options (#) exercisable | Number of securities underlying unexercised options (#) unexercisable | Option exercise price ($) | Option expiration date | |||||||||||||||||||||||||||||||||
Benjamin J. Zeskind, Ph.D. | 9/20/2019 | 203,500 | (1) | — | 3.01 | 12/15/2029 | ||||||||||||||||||||||||||||||||
5/4/2021 | 69,270 | (2) | 105,730 | (2) | 9.74 | 5/5/2031 | ||||||||||||||||||||||||||||||||
1/1/2022 | 10,351 | (4) | 35,264 | (4) | 10.63 | 2/9/2027 | ||||||||||||||||||||||||||||||||
1/1/2022 | 35,963 | (4) | 120,522 | (4) | 9.66 | 2/9//2032 | ||||||||||||||||||||||||||||||||
Brett Hall, Ph.D. | 5/5/2018 | 91,000 | (3) | — | 3.01 | 2/24/2029 | ||||||||||||||||||||||||||||||||
11/1/2019 | 155,400 | (3) | 46,200 | (3) | 3.01 | 12/16/2029 | ||||||||||||||||||||||||||||||||
5/4/2021 | 69,270 | (2) | 105,730 | (2) | 9.74 | 5/5/2031 | ||||||||||||||||||||||||||||||||
1/1/2022 | 19,043 | (4) | 64,057 | (4) | 9.66 | 2/9/2032 | ||||||||||||||||||||||||||||||||
Scott Barrett, M.D. | 12/16/2019 | 150,112 | (2) | 44,628 | (2) | 3.01 | 12/16/2029 | |||||||||||||||||||||||||||||||
1/1/2022 | 16,465 | (4) | 55,385 | (4) | 9.66 | 2/9/2032 |
Name | | Fees earned or paid in cash ($) | | Option awards ($)(1) | | All other compensation ($) | | Total ($) | | Name | Fees earned or paid in cash ($) | Option awards ($)(1) | All other compensation ($) | Total ($) | |||||||||||||||||||||||||||||||||||||
Ann E. Berman | | | | 22,745 | | | | | 344,218 | | | | | — | | | | | 366,963 | | | Ann E. Berman | 54,000 | 53,608 | — | 107,608 | |||||||||||||||||||||||||
Robert J. Carpenter | | | | 36,012 | | | | | — | | | | | — | | | | | 36,012 | | | Robert J. Carpenter | 83,174 | 53,608 | — | 136,782 | |||||||||||||||||||||||||
Peter Feinberg | | | | 14,742 | | | | | — | | | | | — | | | | | 14,742 | | | Peter Feinberg | 35,000 | 53,608 | — | 88,608 | |||||||||||||||||||||||||
Laurie B. Keating | | | | 22,113 | | | | | 202,096 | | | | | — | | | | | 224,209 | | | Laurie B. Keating | 52,500 | 53,608 | — | 106,108 | |||||||||||||||||||||||||
Andrew Phillips, Ph.D.(2) | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||
Diana F. Hausman, MD(2) | | | | — | | | | | — | | | | | — | | | | | — | | | Diana F. Hausman, MD(2) | 37,454 | 286,034 | — | 323,488 |
Name | | | Options outstanding at fiscal year end (exercisable) | | | Options outstanding at fiscal year end (unexercisable) | | | Unvested restricted shares outstanding at fiscal year end | | |||||||||
Ann E. Berman | | | | | — | | | | | | 28,372 | | | | | | — | | |
Robert J. Carpenter | | | | | 55,576 | | | | | | 55,577 | | | | | | — | | |
Peter Feinberg | | | | | 55,576 | | | | | | 55,577 | | | | | | — | | |
Laurie B. Keating | | | | | — | | | | | | 60,074 | | | | | | — | | |
Andrew Phillips, Ph.D. | | | | | — | | | | | | — | | | | | | — | | |
Diana F. Hausman | | | | | — | | | | | | — | | | | | | — | | |
Name | Options outstanding at fiscal year end (exercisable) | Options outstanding at fiscal year end (unexercisable) | Unvested restricted shares outstanding at fiscal year end | |||||||||||||||||
Ann E. Berman | 17,148 | 25,424 | — | |||||||||||||||||
Robert J. Carpenter | 90,464 | 34,889 | — | |||||||||||||||||
Peter Feinberg | 90,464 | 34,889 | — | |||||||||||||||||
Laurie B. Keating | 33,382 | 40,892 | — | |||||||||||||||||
Diana F. Hausman | 10,792 | 20,593 | — |
Plan Category | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | | Weighted- Average Exercise Price of Outstanding Options, Warrants, and Rights | | Number of Securities Available for Future Issuance Under Equity Compensation Plans (excludes securities Reflected in first column)(1) | | Plan Category | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | Weighted- Average Exercise Price of Outstanding Options, Warrants, and Rights | Number of Securities Available for Future Issuance Under Equity Compensation Plans (excludes securities Reflected in first column)(1) | |||||||||||||||||||||||||||||||||||||
Equity compensation plans approved by security holders(2) | | | | 2,859,568(3) | | | | $ | 6.55(4) | | | | | 2,618,936(5) | | | Equity compensation plans approved by security holders(2) | 3,559,041 | (3) | $7.36 | (4) | 3,066,412 | (5) | |||||||||||||||||||||||||
Equity compensation plans not approved by security holders | | | | — | | | | | — | | | | | — | | | Equity compensation plans not approved by security holders | — | — | — | ||||||||||||||||||||||||||||
Total | | | | 2,859,568 | | | | $ | 6.55 | | | | | 2,618,936 | | | Total | 3,559,041 | $7.36 | 3,066,412 |
| | | Shares of Class A Common Stock Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
Entities advised or sub-advised by T. Rowe Price Associates, Inc. and T. Rowe Price Health Sciences Fund, Inc.(1) | | | | | 3,188,505 | | | | | | 12.1% | | |
Merrin Investors LLC(2) | | | | | 2,405,386 | | | | | | 9.1% | | |
Entities affiliated with Cormorant Asset Management, LP(3) | | | | | 2,252,628 | | | | | | 8.5% | | |
Citadel Multi-Strategy Equities Master Fund Ltd.(4) | | | | | 2,058,148 | | | | | | 7.8% | | |
BlackRock, Inc.(5) | | | | | 1,716,170 | | | | | | 6.5% | | |
Named Executive Officers and Directors | | | | | | | | | | | | | |
Benjamin J. Zeskind, Ph.D.(6) | | | | | 3,426,515 | | | | | | 12.9% | | |
Biren Amin(7) | | | | | 83,820 | | | | | | * | | |
Brett Hall, Ph.D.(8) | | | | | 578,680 | | | | | | 2.2% | | |
Ann E. Berman(9) | | | | | 9,500 | | | | | | * | | |
Robert J. Carpenter(10) | | | | | 1,215,993 | | | | | | 4.6% | | |
Peter Feinberg(11) | | | | | 1,063,218 | | | | | | 4.0% | | |
Laurie B. Keating(12) | | | | | 24,521 | | | | | | * | | |
Diana F. Hausman, MD(13) | | | | | 2,800 | | | | | | * | | |
All current executive officers and directors as a group (10 persons)(14) | | | | | 6,547,148 | | | | | | 23.9% | | |
Shares of Class A Common Stock Beneficially Owned | Percentage of Shares Beneficially Owned | ||||||||||
Greater than 5% Stockholders | |||||||||||
Entities advised or sub-advised by T. Rowe Price Associates, Inc. and T. Rowe Price Health Sciences Fund, Inc.(1) | 3,619,560 | 12.4 | % | ||||||||
Merrin Investors LLC(2) | 2,405,386 | 8.2 | % | ||||||||
Entities affiliated with Cormorant Asset Management, LP(3) | 4,204,364 | 14.4 | % | ||||||||
Citadel Multi-Strategy Equities Master Fund Ltd.(4) | 2,141,497 | 7.3 | % | ||||||||
Named Executive Officers and Directors | |||||||||||
Benjamin J. Zeskind, Ph.D.(5) | 3,542,665 | 12.0 | % | ||||||||
Scott Barrett, M.D.(6) | 202,963 | * | |||||||||
Brett Hall, Ph.D.(7) | 722,468 | 2.4 | % | ||||||||
Ann E. Berman(8) | 35,519 | * | |||||||||
Robert J. Carpenter(9) | 1,256,798 | 4.3 | % | ||||||||
Peter Feinberg(10) | 1,104,023 | 3.8 | % | ||||||||
Laurie B. Keating(11) | 59,555 | * | |||||||||
Diana F. Hausman, MD(12) | 16,869 | * | |||||||||
All current executive officers and directors as a group (12 persons)(13) | 7,056,307 | 23.0 | % |
Participants(1) | | | Series A Preferred Stock | | | Aggregate Purchase Price (in thousands) | | ||||||
Merrin Investors LLC | | | | | 409,289 | | | | | $ | 3,500 | | |
Robert J. Carpenter | | | | | 67,561 | | | | | $ | 512 | | |
Benjamin J. Zeskind, Ph.D. | | | | | 29,234 | | | | | $ | 250 | | |
Brett Hall, Ph.D. | | | | | 1,169 | | | | | $ | 10 | | |
Scott Barrett, M.D. | | | | | 2,338 | | | | | $ | 20 | | |
Entities affiliated with Peter Feinberg(2) | | | | | 213,215 | | | | | $ | 1,509 | | |
Participants(1) | | Series B Preferred Stock | | Aggregate Purchase Price (in thousands) | | Participants(1) | Series B Preferred Stock | Aggregate Purchase Price (in thousands) | |||||||||||||||||||
Merrin Investors LLC | | | | 291,878 | | | | $ | 3,000 | | | Merrin Investors LLC | 291,878 | $3,000 | |||||||||||||
Entities affiliated with Cormorant Asset Management, LP (2) | | | | 1,216,163 | | | | $ | 12,500 | | | Entities affiliated with Cormorant Asset Management, LP(2) | 1,216,163 | $12,500 | |||||||||||||
Entities advised or sub-advised by T. Rowe Price Associates, Inc. (3) | | | | 778,345 | | | | $ | 8,000 | | | Entities advised or sub-advised by T. Rowe Price Associates, Inc.(3) | 778,345 | $8,000 | |||||||||||||
Entities affiliated with Blackrock, Inc.(4) | | | | 583,758 | | | | $ | 6,000 | | | Entities affiliated with Blackrock, Inc.(4) | 583,758 | $6,000 | |||||||||||||
Citadel Multi-Strategy Equities Master Fund Ltd. | | | | 1,216,165 | | | | $ | 12,500 | | | Citadel Multi-Strategy Equities Master Fund Ltd. | 1,216,165 | $12,500 | |||||||||||||
Benjamin J. Zeskind, Ph.D. | | | | 5,837 | | | | $ | 60 | | | Benjamin J. Zeskind, Ph.D. | 5,837 | $60 | |||||||||||||
Robert J. Carpenter | | | | 87,563 | | | | $ | 900 | | | Robert J. Carpenter | 87,563 | $900 | |||||||||||||
Brett Hall, Ph.D. | | | | 2,431 | | | | $ | 25 | | | Brett Hall, Ph.D. | 2,431 | $25 | |||||||||||||
Scott Barrett, M.D. | | | | 1,945 | | | | $ | 20 | | | Scott Barrett, M.D. | 1,945 | $20 | |||||||||||||
Biren Amin | | | | 1,945 | | | | $ | 20 | | | Biren Amin | 1,945 | $20 | |||||||||||||
Entities affiliated with Peter Feinberg(5) | | | | 87,560 | | | | $ | 900 | | | Entities affiliated with Peter Feinberg(5) | 87,560 | $900 |
Participants(1) | | Class A Common Stock | | Aggregate Purchase Price (in thousands) | | Participants(1) | Class A Common Stock | Aggregate Purchase Price (in thousands) | |||||||||||||||||||
Merrin Investors LLC | | | | 1,300,000 | | | | $ | 19,500 | | | Merrin Investors LLC | 1,300,000 | $19,500 | |||||||||||||
Entities affiliated with Cormorant Asset Management, LP | | | | 550,000 | | | | $ | 8,250 | | | Entities affiliated with Cormorant Asset Management, LP | 550,000 | $8,250 | |||||||||||||
Entities advised or sub-advised by T. Rowe Price Associates, Inc. | | | | 1,900,000 | | | | $ | 28,500 | | | Entities advised or sub-advised by T. Rowe Price Associates, Inc. | 1,900,000 | $28,500 | |||||||||||||
Entities affiliated with Blackrock, Inc. | | | | 300,000 | | | | $ | 4,500 | | | Entities affiliated with Blackrock, Inc. | 300,000 | $4,500 | |||||||||||||
Entities affiliated with Citadel Multi-Strategy Equities Master Fund Ltd. | | | | 400,000 | | | | $ | 12,500 | | | Entities affiliated with Citadel Multi-Strategy Equities Master Fund Ltd. | 400,000 | $12,500 | |||||||||||||
Benjamin J. Zeskind, Ph.D. | | | | 2,098 | | | | $ | 31 | | | Benjamin J. Zeskind, Ph.D. | 2,098 | $31 | |||||||||||||
Robert J. Carpenter | | | | 325,000 | | | | $ | 4,875 | | | Robert J. Carpenter | 325,000 | $4,875 | |||||||||||||
Brett Hall, Ph.D. | | | | 1,353 | | | | $ | 20 | | | Brett Hall, Ph.D. | 1,353 | $20 | |||||||||||||
Scott Barrett, M.D. | | | | 667 | | | | $ | 10 | | | Scott Barrett, M.D. | 667 | $10 | |||||||||||||
Biren Amin | | | | 4,175 | | | | $ | 63 | | | Biren Amin | 4,175 | $63 | |||||||||||||
Entities affiliated with Peter Feinberg(2) | | | | 291,667 | | | | $ | 4,375 | | | Entities affiliated with Peter Feinberg(2) | 291,667 | $4,375 | |||||||||||||
Michael D. Bookman | | | | 1,402 | | | | $ | 21 | | | Michael D. Bookman | 1,402 | $21 | |||||||||||||
Laurie B. Keating | | | | 7,000 | | | | $ | 110 | | | Laurie B. Keating | 7,000 | $110 | |||||||||||||
Ann E. Berman | | | | 3,500 | | | | $ | 53 | | | Ann E. Berman | 3,500 | $53 |
By Order of the Board of Directors | ||||||||
/s/ Michael D. Bookman | ||||||||
Michael D. Bookman Chief Legal Officer and Secretary | ||||||||
Cambridge, Massachusetts May 1, 2023 |